Last reviewed 2026-05-14 · How we verify

2030 Pharmaceutical Patent Cliff

64 marketed drugs with patents expiring in 2030, joined to sponsor + therapeutic area + drug class. Forward-looking forecast. Sourced from FDA Orange Book + USPTO Patent Public Search.

Sponsors most affected (10)

1. Merck & Co. · 6 drugs
2. Pfizer · 6 drugs
3. Unknown · 4 drugs
4. Novartis · 3 drugs
5. AbbVie · 3 drugs
6. AstraZeneca · 2 drugs
7. Boehringer Ingelheim · 2 drugs
8. Accord Hlthcare · 2 drugs
9. Helsinn Hlthcare · 2 drugs
10. Hisamitsu Pharm Co · 1 drug

By therapeutic area

Oncology (25)

• 2030-01-15 — Cometriq · Exelixis · Kinase Inhibitor
• 2030-02-12 — Decadron · Generic (originally Merck) · Corticosteroid [EPC] · Method of Use
• 2030-02-12 — Decadron-La · Merck & Co. · Corticosteroid · Method of Use
• 2030-03-19 — Xyosted (Autoinjector) · Endo · Androgen
• 2030-03-19 — Trexall · Generic (originally Lederle Laboratories) · Antifolate, DMARD · Formulation
• 2030-04-15 — Rapamune · Pfizer · mTOR Inhibitor Immunosuppressant [EPC] · Formulation
• 2030-04-23 — Arthrotec · Pfizer · diclofenac
• 2030-04-27 — Duragesic · Johnson & Johnson (Janssen Pharmaceutica) · Synthetic opioid analgesic · Formulation
• 2030-04-30 — Aldara · Bausch Health · imiquimod · Method of Use
• 2030-05-01 — Rowasa · Meda Pharms · Aminosalicylate [EPC]
• 2030-05-25 — Kisqali · Novartis · Kinase Inhibitor
• 2030-05-26 — Venclexta · AbbVie · BCL-2 Inhibitor [EPC]
• 2030-06-03 — Vidaza · Bristol-Myers Squibb · Nucleoside Metabolic Inhibitor [EPC] · Formulation
• 2030-06-10 — Mavyret · AbbVie · Hepatitis C Virus NS5A Inhibitor [EPC]
• 2030-06-10 — Viekira Pak (Copackaged) · AbbVie · Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
• 2030-06-28 — Gemzar · Accord Hlthcare · Nucleoside metabolic inhibitor · Formulation
• 2030-07-04 — Estrace · Pfizer · Estrogen · Compound
• 2030-07-04 — Estring · Pfizer Inc. · Combined Oral Contraceptive (COC) · Compound
• 2030-08-22 — Inqovi · Otsuka · Nucleoside Metabolic Inhibitor [EPC]
• 2030-08-27 — Mektovi · Pfizer
• 2030-08-31 — Diprolene · Merck & Co. · Corticosteroid · Formulation
• 2030-10-27 — Jevtana Kit · Accord Hlthcare · Microtubule Inhibitor · Method of Use
• 2030-11-18 — Akynzeo · Helsinn Hlthcare · Serotonin-3 Receptor Antagonist [EPC]
• 2030-11-18 — Akynzeo · Helsinn Hlthcare · Serotonin-3 Receptor Antagonist [EPC]
• 2030-12-13 — Sandimmune · Novartis · Calcineurin Inhibitor Immunosuppressant [EPC]

Metabolic (11)

• 2030-01-07 — Byetta · AstraZeneca · GLP-1 Receptor Agonist [EPC]
• 2030-02-05 — Tradjenta · Boehringer Ingelheim · Dipeptidyl Peptidase 4 Inhibitor [EPC]
• 2030-02-10 — Sodium Thiosulfate · Us Army · sodium thiosulfate · Compound
• 2030-03-31 — Ongentys · Neurocrine Biosciences · Catechol-O-Methyltransferase Inhibitor [EPC]
• 2030-05-02 — Ibsrela · Ardelyx Inc
• 2030-05-16 — Reglan · Hikma · Prokinetic agent · Formulation
• 2030-05-28 — Cuvposa · Shionogi · Anticholinergic
• 2030-07-04 — Femring · Apil · Estrogen · Compound
• 2030-10-08 — Tygacil · Pfizer · Tetracycline
• 2030-10-30 — Glycopyrrolate · Yonsei University · Formulation
• 2030-11-04 — Vantobra · Pfizer · tobramycin

Immunology (10)

• 2030-01-03 — Salonpas · Non-Standardized Plant Allergenic Extract [EPC]
• 2030-01-03 — Salonpas · Hisamitsu Pharm Co · methyl salicylate
• 2030-02-12 — Dexamethasone Sodium Phosphate · Merck & Co. · Corticosteroid · Method of Use
• 2030-04-19 — Acetaminophen · Polymedica · acetaminophen
• 2030-04-23 — Indocin Sr · Nonsteroidal Anti-inflammatory Drug [EPC] · Formulation
• 2030-05-01 — MESALAMINE · Aminosalicylate [EPC] · Method of Use
• 2030-05-26 — Mobic · Boehringer Ingelheim · Nonsteroidal Anti-inflammatory Drug [EPC] · Formulation
• 2030-08-31 — Temovate · Fougera Pharms · Corticosteroid · Formulation
• 2030-09-14 — Advil · Generic (originally Boots Group) · Nonsteroidal Anti-inflammatory Drug [EPC] · Method of Use
• 2030-12-13 — Sandimmune · Novartis AG (originally Sandoz) · Calcineurin inhibitor (immunosuppressant) · Formulation

Cardiovascular (5)

• 2030-02-04 — Edarbi · Arbor Pharms Ireland · Angiotensin 2 Receptor Blocker
• 2030-02-04 — Combipres · University Hospital Birmingham · Thiazide-like Diuretic
• 2030-02-23 — Zocor · Merck & Co. · HMG-CoA Reductase Inhibitor [EPC] · Formulation
• 2030-04-17 — Brilinta · AstraZeneca · P2Y12 Platelet Inhibitor [EPC] · Formulation
• 2030-05-28 — Proventil · Merck & Co. · beta2-Adrenergic Agonist

Neuroscience (3)

• 2030-03-29 — Abilify · Generic (originally Otsuka/BMS) · Third-generation antipsychotic (D2 partial agonist) · Formulation
• 2030-04-27 — Cipro · Bayer AG · Fluoroquinolone antibiotic · Method of Use
• 2030-06-16 — Imitrex · GSK · Serotonin-1b and Serotonin-1d Receptor Agonist · Formulation

Infectious Disease (3)

• 2030-10-08 — Avycaz · Cerexa Inc · beta Lactamase Inhibitor [EPC]
• 2030-10-08 — Tygacil · Fresenius Kabi · Tetracycline-class Antibacterial [EPC]
• 2030-11-04 — Tobi · Novartis · Formulation

Women's Health (1)

• 2030-01-21 — Endometrin · Ferring · Progesterone [EPC] · Method of Use

Hematology (1)

• 2030-01-23 — Ferrlecit · Vifor Fresenius · Phosphate Binder [EPC]

Bone (1)

• 2030-02-08 — Ortho-Novum 10/11-21 · Merck & Co. · Estrogen

Respiratory (1)

• 2030-03-08 — Breo Ellipta · Glaxo Grp Ltd · beta2-Adrenergic Agonist

Gastroenterology (1)

• 2030-07-13 — Zofran · GSK (originally Glaxo) · 5-HT3 receptor antagonist (antiemetic) · Formulation

Nephrology (1)

• 2030-09-07 — Rayaldee · calcifediol · Formulation

Pain (1)

• 2030-12-10 — OxyContin · Purdue Pharma · Formulation

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

• Marketed-drug events RSS
• All 2030 pharma events (approvals + readouts + patents)

Related

• Biosimilar tracker — who's competing for each post-cliff originator
• Patent cliff revenue calculator
• 2030 patent expiries dataset (CSV / JSON)